Product Information
BRILINTA 60 MG TABLET is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $7.4192 per EA under NDC 00186077660. Its NADAC has been published 563 times since Dec 23, 2015.
FDA first approved this application on Jul 20, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Ticagrelor market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
60 mg/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00186077660
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TICAGRELORApproval Type
New Drug (NDA)
FDA Application
NDA022433FDA Approved
7/20/2011
TE Code
AB
On Market Since
9/4/2015
Pharmacological Classes
Price Statistics
The NADAC for BRILINTA 60 MG TABLET has been published 563 times since Dec 23, 2015, and over the history we have for it it has risen 62.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.4192 per EA |
|---|---|
| All-time high | $7.4307 (Jul 15, 2026) |
| All-time low | $4.5792 (Dec 23, 2015) |
| 52-week high | $7.4307 |
| 52-week low | $7.4192 |
| Median price | $6.4782 |
| Average price | $6.3831 |
| Largest weekly change | +8.0% (Jan 13, 2016) |
| Weeks tracked | 563 |
| Tracking since | Dec 23, 2015 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 96% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AstraZeneca Pharmaceuticals LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ticagrelor market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
P2Y12 Platelet Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BRILINTA 60 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BRILINTA 60 MG TABLET, manufactured by AstraZeneca Pharmaceuticals LP, is $7.4192 per EA (NDC 00186077660), effective Sep 30, 2026.
How has the price of BRILINTA 60 MG TABLET changed over time?
Over the history we have for it, the NADAC for BRILINTA 60 MG TABLET has risen 62.0%. It has been tracked across 563 weekly CMS publications since Dec 23, 2015.
What are the highest and lowest recorded NADAC prices for BRILINTA 60 MG TABLET?
Since Dec 23, 2015, the NADAC for BRILINTA 60 MG TABLET has ranged from a low of $4.5792 (Dec 23, 2015) to a high of $7.4307 (Jul 15, 2026), with a median of $6.4782 per EA.
Are there cheaper alternatives to BRILINTA 60 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TICAGRELOR 60 MG TABLET, is $0.2821 per EA — about 96% below BRILINTA 60 MG TABLET.
Who manufactures BRILINTA 60 MG TABLET?
BRILINTA 60 MG TABLET (NDC 00186077660) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.